Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency
The entire production process of the purified siRNA-EMVs took approximately 4 hours. The erythrocyte marker CD47 offered protection against macrophage recognition in the spleen and in the blood. The excellent biocompatibility and pharmacokinetic properties of these materials make them promising platforms for future improvements, ie, active targeting and codelivery with conventional chemotherapeutics.
Authors
- Nina Kostevšek (ORCID: https://orcid.org/0000-0002-6551-0250)
- Giulia Della Pelle (ORCID: https://orcid.org/0000-0002-8110-1932)
- Igor Križaj (ORCID: https://orcid.org/0000-0003-0203-0708)
- Tim Božič (ORCID: https://orcid.org/0000-0001-6468-8287)
- Boštjan Markelc (ORCID: https://orcid.org/0000-0002-8674-702X)
- Iztok Urbančič (ORCID: https://orcid.org/0000-0003-3603-6585)
- Matic Kisovec (ORCID: https://orcid.org/0000-0003-4131-2177)
- Mateja Erdani Kreft (ORCID: https://orcid.org/0000-0001-6486-165X)
- Marjetka Podobnik (ORCID: https://orcid.org/0000-0001-6786-9737)
- Kristina Žagar Soderžnik (ORCID: https://orcid.org/0000-0001-9987-7221)
- Samo Hudoklin (ORCID: https://orcid.org/0000-0002-2144-292X)
- Jernej Šribar (ORCID: https://orcid.org/0000-0003-0646-5602)
Institutions
- University of Ljubljana (SI)
- Jožef Stefan Institute (SI)
- Institute of Oncology Ljubljana (SI)
- Jožef Stefan International Postgraduate School (SI)
- National Institute of Chemistry (SI)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/ijn.s504644
- Citations
- 8
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 6.45